Elon Musk Seeks $134 Billion in Lawsuit Against OpenAI and Microsoft Over Alleged Wrongful Gains 
Pop Mart Shares Surge in Hong Kong After First Buyback in Nearly Two Years 
Trump Criticizes NYSE Texas Expansion, Calls Dallas Exchange a Blow to New York 
U.S. Transportation Board Sends Union Pacific–Norfolk Southern Merger Back for Revision 
China’s AI Models Narrow the Gap With the West, Says Google DeepMind CEO 
Brazil Supreme Court Orders Asset Freeze of Nelson Tanure Amid Banco Master Investigation 
TSMC Shares Hit Record High as AI Chip Demand Fuels Strong Q4 Earnings 
Baidu Shares Rise in Hong Kong After Apollo Go Robotaxi Launch in Abu Dhabi 
Micron to Buy Powerchip Fab for $1.8 Billion, Shares Surge Nearly 10% 
Proposed Rio Tinto–Glencore Merger Faces China Regulatory Hurdles and Asset Sale Pressure 
China Halts Shipments of Nvidia H200 AI Chips, Forcing Suppliers to Pause Production 
Toyota Industries Buyout Faces Resistance as Elliott Rejects Higher Offer 
Publishers Seek to Join Lawsuit Against Google Over Alleged AI Copyright Infringement 
Anthropic Appoints Former Microsoft Executive Irina Ghose to Lead India Expansion 
Syrah Resources and Tesla Extend Deadline on Graphite Supply Dispute to March 
DURHAM, N.C., April 26, 2017 -- Heat Biologics, Inc. (“Heat”) (Nasdaq:HTBX), a leader in the development of immunotherapies designed to activate a patient’s immune system against cancer, announced today that Jeff Wolf, Heat’s Founder and CEO, will present at PIONEERS 2017, presented by Joseph Gunnar & Co., on Tuesday, May 2, 2017, at 11:30 a.m. ET. The event will be held at the Mandarin Oriental Hotel in New York City.
Management will be available to meet with investors during the conference. For more information about the conference or to schedule a one-on-one meeting with management, please contact your Joseph Gunnar & Co. representative, email [email protected] or email [email protected].
About Heat Biologics, Inc.
Heat Biologics, Inc. (Nasdaq:HTBX) is an immuno-oncology company developing novel therapies that are designed to activate a patient’s immune system against cancer utilizing an engineered form of gp96, a protein that robustly activates the immune system. Heat’s highly specific T cell-stimulating therapeutic vaccine platform technologies, ImPACT and ComPACT, in combination with other therapies, such as checkpoint inhibitors, are designed to address three distinct but synergistic mechanisms of action: robust activation of CD8+ “killer” T cells (one of the human immune system’s most potent weapons against cancer); reversal of tumor-induced immune suppression; and T cell co-stimulation to further enhance patients’ immune response. Currently, Heat is conducting a Phase 2 trial with HS-110 (viagenpumatucel-L) in combination with an anti-PD-1 checkpoint inhibitor to treat patients with non-small cell lung cancer (NSCLC) and a Phase 2 trial with HS-410 (vesigenurtacel-L) in patients with non-muscle invasive bladder cancer (NMIBC).
Heat’s wholly-owned subsidiary, Zolovax, Inc., is developing therapeutic and preventative vaccines to treat infectious diseases based on Heat’s gp96 vaccine technology, with a current focus on the development of a Zika vaccine in conjunction with the University of Miami.
For more information, please visit www.heatbio.com.
For Investor Inquiries: David Waldman 919-240-7133 [email protected] For Media Inquiries: Deanne Eagle Planet Communications 917-837-5866 [email protected]
